MYOV stock forecast
Our latest prediction for Myovant Sciences Ltd.'s stock price was made on the March 19, 2018 when the stock price was at 18.26$.
In the short term (2weeks), MYOV's stock price should underperform the market by -0.52%. During that period the price should oscillate between -12.18% and +9.54%.
In the medium term (3months), MYOV's stock price should underperform the market by -14.02%. During that period the price should oscillate between -33.75% and +18.78%.Get email alerts
About Myovant Sciences Ltd.
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.80$ per share.
The book value per share is 0.88$
Three months stock forecastMarch 19, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|